Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01777802 · ClinicalTrials.gov registry record
Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy
A clinical trial of Breast Cancer and Prostate Cancer, sponsored by Mayo Clinic.
- Completed
- Registry status
- 98
- Enrollment target
- 1
- Study location
NCT01777802: Completed study of Breast Cancer and Prostate Cancer, sponsored by Mayo Clinic.
NCT01777802 is a study of Breast Cancer and Prostate Cancer that has completed, run by Mayo Clinic. The registered enrollment target is 98 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01777802, a study of Breast Cancer and Prostate Cancer, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- 98 participants
- Enrollment target
- 1
- Study location
Study Summary
Success of cancer immunotherapy is limited by the ability of solid tumors to evade local and systemic antitumoral immune responses. Several mechanisms of tumor immune evasion have been identified, including low intratumor expression of antigens and elevated expression of inhibitory co-regulatory molecules. An effective immunotherapy is one which would induce necrotic cell death and accompanying proinflammatory cytokine induction. Stereotactic Body Radiotherapy (SBRT) or Intensity Modulated Radiotherapy (IMRT) or brachytherapy, which is capable of delivering high, conformal radiation doses (\>8 Gy) of tumor ablative radiation may be an effective means of conditioning a tumor bed to a state favorable to the initiation of robust antitumoral immune responses.
Primary Outcome
Changes in baseline circulating tumor reactive immune markers after radiotherapy.
Conditions Studied
Interventions
- RADIATION Brachytherapy
- RADIATION SBRT
- RADIATION IMRT
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2013-01-02 |
| Est. Completion | 2023-06-21 |
What the finished NCT01777802 record still lists
NCT01777802 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 98 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower).
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which Brachytherapy is the first listed.
NCT01777802 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT01777802 about?
NCT01777802 is a clinical study titled "Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy". Success of cancer immunotherapy is limited by the ability of solid tumors to evade local and systemic antitumoral immune responses. Several mechanisms of tumor immune evasion have been identified, including low intratumor expression of antigens and elevated expression of inhibitory co-regulatory mol...
What is the current status of trial NCT01777802?
This trial is currently completed. The enrollment target is 98 participants. The study started on 2013-01-02. Estimated completion is 2023-06-21.
What conditions does trial NCT01777802 study?
This clinical trial studies the following conditions: Breast Cancer, Prostate Cancer, Lung Cancer, Melanoma.
What interventions are being tested in trial NCT01777802?
The interventions under investigation include: Brachytherapy (RADIATION), SBRT (RADIATION), IMRT (RADIATION).
Who is sponsoring clinical trial NCT01777802?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01777802 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01777802's enrollment target sits among peer trials
98 598th of 1224 higher than 622 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
- NCT04860141 · 98 participants · Phase 4
Efficacy of Preoperative Administration of Gabapentin in 3rd Molar Dental Extraction.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI